Status:
RECRUITING
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
Lead Sponsor:
Duke University
Collaborating Sponsors:
Bayer
Boehringer Ingelheim
Conditions:
Chronic Kidney Disease(CKD)
Type 2 DM
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
Detailed Description
IRIS-CKD Screening Program: will focus on CKD screening in T2D. We will identify patients with T2D that have not received appropriate screening for CKD within the last 15 months and randomize patients...
Eligibility Criteria
Inclusion
- Screening Program-
- Adults with type 2 diabetes (T2D)
- Receiving primary care within the healthcare system, Primary Care Provider (PCP) visit within the past 24 months (any PCP provider, including APP).
- Lack of estimated glomerular filtration rate (eGFR) and/or urine albumin- creatinine ratio (UACR) measurement in the prior 15 months within the EHR
Exclusion
- • Chronic kidney disease (CKD) diagnosis
Key Trial Info
Start Date :
October 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2027
Estimated Enrollment :
750 Patients enrolled
Trial Details
Trial ID
NCT06906627
Start Date
October 28 2025
End Date
April 1 2027
Last Update
December 12 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama
Birmingham, Alabama, United States, 35233
2
Essentia Health
Duluth, Minnesota, United States, 55805
3
Duke University
Durham, North Carolina, United States, 27707
4
Baylor Scott & White
Temple, Texas, United States, 76508